Balancing Stealth and Targetability: cCPP‐ and PEG‐Modified Liposomes for the Targeted Delivery of Anti‐HER2 Nanobodies
Advanced Science · 2026
DOI: 10.1002/advs.75646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Giulia Pander und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany. Hauptthemen laut MEDLINE: Liposomes, Polyethylene Glycols, Single-Domain Antibodies, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EXIST Forschungstransfer.
Abstract (Originalsprache)
Nanobodies (Nbs) are considered promising antibody fragments for overcoming limitations in precision oncology due to their high specificity and deep tissue penetration. However, their therapeutic potential remains limited by their rapid renal clearance. In this study, anti‐HER2 Nb‐loaded liposomes with dual functionalization combining polyethylene glycol 2000 (PEG) and cyclic cell‐penetrating peptides are developed to ameliorate their pharmacokinetic behavior while retaining binding specificity. Liposomal formulations with high encapsulation efficiencies are produced with dual centrifugation. Biophysical characterization reveals that PEGylation effectively mitigates cCPP‐induced membrane destabilization, ensuring structural integrity. In vitro assays confirm that, despite the steric shielding by PEG, the encapsulated Nbs retain their functionality and specific binding to HER2‐overexpressing cells. In vivo studies in zebrafish larvae demonstrate excellent biocompatibility and lack of immunogenicity. Crucially, liposomal encapsulation significantly modulates the pharmacokinetic profile of Nbs in rats, reducing renal accumulation compared to free Nbs. This study presents a robust liposomal platform that successfully balances the stealth properties of PEG with the functional benefits of cCPPs. Consequently, this platform offers an effective strategy to enhance the therapeutic window of low‐molecular‐weight biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology, Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany.
- Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Pharmaceutical Technology, University of Basel, Basel, Switzerland.
- Lipospec GmbH, Augsburg, Germany.
- Physiology, Institute of Theoretical Medicine, University of Augsburg, Universitätsstraße 2, Augsburg, Germany.
Förderung
- EXIST Forschungstransfer
Zitieren
APA
Pander, G., Palacios Cisneros, M. D. P., Certa, C., Stierli, M., Beck, K., Färber, N., Blank, L., Tanner, F., Mühlberg, E., Wohlfart, S., Kleist, C., Huwyler, J., Fricker, G., Mier, W., & Uhl, P. (2026). Balancing Stealth and Targetability: cCPP‐ and PEG‐Modified Liposomes for the Targeted Delivery of Anti‐HER2 Nanobodies. Advanced Science. https://doi.org/10.1002/advs.75646
Vancouver
Pander G, Palacios Cisneros MDP, Certa C, Stierli M, Beck K, Färber N, et al. Balancing Stealth and Targetability: cCPP‐ and PEG‐Modified Liposomes for the Targeted Delivery of Anti‐HER2 Nanobodies. Advanced Science. 2026. doi:10.1002/advs.75646
BibTeX
@article{Pander2026,
author = {Pander, Giulia and Palacios Cisneros, Maria Del Pilar and Certa, Clara and Stierli, Megan and Beck, Katharina and Färber, Nicolas and Blank, Lisa and Tanner, Fiona and Mühlberg, Eric and Wohlfart, Sabrina and Kleist, Christian and Huwyler, Jörg and Fricker, Gert and Mier, Walter and Uhl, Philipp},
title = {Balancing Stealth and Targetability: cCPP‐ and PEG‐Modified Liposomes for the Targeted Delivery of Anti‐HER2 Nanobodies},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.75646}
}
EUVIMED